妊娠期丙型肝炎:筛查、治疗与管理
美国孕妇丙型肝炎病毒感染率为1-2.5%,母婴传播风险约5%,感染与胎儿生长受限和低出生体重等不良胎儿结局风险增加相关。本文讨论妊娠期丙型肝炎病毒的现有证据,并给出筛查、治疗和管理的推荐。
要点
- 建议在首次产前检查时对有感染风险增加的孕妇检测抗丙型肝炎病毒抗体(GRADE 1B)。
- 不建议仅因丙型肝炎病毒阳性而剖宫产(GRADE 1B);不因丙型肝炎病毒阳性而劝阻母乳喂养(GRADE 1A)。
- 直接抗病毒方案目前未获批用于妊娠期,仅可在临床试验中使用或推迟至产后(GRADE 1C)。
核心结论
- 本文目的是讨论妊娠期丙型肝炎病毒的现有证据,并就妊娠期该病的筛查、治疗和管理提供推荐。
研究设计与样本
- 本文为美国母胎医学会(Society for Maternal-Fetal Medicine)发布的推荐文件,未报告系统检索方法。
主要发现
- 美国孕妇丙型肝炎病毒感染率为1-2.5%,母婴传播风险约5%。
- 丙型肝炎病毒可在宫内或围产期传播给婴儿,妊娠期感染与胎儿生长受限和低出生体重等不良胎儿结局风险增加相关。
关键数值与推荐
- 推荐产科照护者在首次产前检查时对有丙型肝炎感染风险增加的孕妇检测抗丙型肝炎病毒抗体;初次结果阴性但持续存在或新出现感染危险因素(如新发或持续使用注射或鼻吸违禁药物)者,应在妊娠后期重复筛查(GRADE 1B)。
- 推荐产科照护者对丙型肝炎病毒阳性孕妇筛查其他性传播疾病,包括HIV、梅毒、淋病、衣原体和乙型肝炎病毒(GRADE 1B)。
- 建议对丙型肝炎病毒患者(包括孕妇)进行戒酒咨询(Best Practice)。
- 推荐直接抗病毒方案仅用于临床试验环境,或将抗病毒治疗推迟至产后,因直接抗病毒方案目前未获批用于妊娠期(GRADE 1C)。
- 建议若要求有创产前诊断检查,应告知孕妇垂直传播风险的数据令人安心但有限;鉴于绒毛膜绒毛取样缺乏数据,推荐羊膜腔穿刺而非绒毛膜绒毛取样(GRADE 2C)。
临床怎么用
- 产科照护者应在首次产前检查时对有风险增加的孕妇检测抗丙型肝炎病毒抗体,并在有持续或新发危险因素时于妊娠后期重复筛查。
- 丙型肝炎病毒阳性孕妇应筛查HIV、梅毒、淋病、衣原体和乙型肝炎病毒,并接受戒酒咨询。
- 直接抗病毒治疗仅可在临床试验中使用或推迟至产后;不因丙型肝炎病毒阳性而剖宫产,产程中避免胎儿内监护、胎膜早破时间延长和会阴切开,不劝阻母乳喂养。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the United States, 1-2.5% of pregnant women are infected with hepatitis C virus, which carries an approximately 5% risk of transmission from mother to infant. Hepatitis C virus can be transmitted to the infant in utero or during the peripartum period, and infection during pregnancy is associated with increased risk of adverse fetal outcomes, including fetal growth restriction and low birthweight. The purpose of this document is to discuss the current evidence regarding hepatitis C virus in pregnancy and to provide recommendations on screening, treatment, and management of this disease during pregnancy. The following are Society for Maternal-Fetal Medicine recommendations: (1) We recommend that obstetric care providers screen women who are at increased risk for hepatitis C infection by testing for anti-hepatitis C virus antibodies at their first prenatal visit. If initial results are negative, hepatitis C screening should be repeated later in pregnancy in women with persistent or new risk factors for hepatitis C infection (eg, new or ongoing use of injected or intranasal illicit drugs) (GRADE 1B). (2) We recommend that obstetric care providers screen hepatitis C virus-positive pregnant women for other sexually transmitted diseases, including HIV, syphilis, gonorrhea, chlamydia, and hepatitis B virus (GRADE 1B). (3) We suggest that patients with hepatitis C virus, including pregnant women, be counseled to abstain from alcohol (Best Practice). (4) We recommend that direct-acting antiviral regimens only be used in the setting of a clinical trial or that antiviral treatment be deferred to the postpartum period as direct-acting antiviral regimens are not currently approved for use in pregnancy (GRADE 1C). (5) We suggest that if invasive prenatal diagnostic testing is requested, women be counseled that data on the risk of vertical transmission are reassuring but limited; amniocentesis is recommended over chorionic villus sampling given the lack of data on the latter (GRADE 2C). (6) We recommend against cesarean delivery solely for the indication of hepatitis C virus (GRADE 1B). (7) We recommend that obstetric care providers avoid internal fetal monitoring, prolonged rupture of membranes, and episiotomy in managing labor in hepatitis C virus-positive women (GRADE 1B). (8) We recommend that providers not discourage breast-feeding based on a positive hepatitis C virus infection status (GRADE 1A).
引用
- Hughes BL, Page CM, Kuller JA, et al. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol. 2017. PMID: 28782502. doi:10.1016/j.ajog.2017.07.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。